Against the hypothesis that the main beneficial effect of mifepristone in inhibiting cancer progression, is by suppressing PGRMC-1 (which in high dosages does suppress PGRMC-1 in cell line studies), is the fact that the lower dosage of mifepristone (200–300 mg) daily, which shows definite clinical benefits in patients with cancer, acts as an agonist, rather than antagonist, for PGRMC-1, and thus may increase cancer aggressiveness [113]. This evidence concerns the gene PGRMC1 and cancer.